#immunotherapy has many facets and #mRNA generates new possibilities for #cancer treatment. DKFZ Immunology Infection and Cancer Society for Immunotherapy of Cancer Mathias Heikenwälder Rajiv Shah, MD HI-TRON Mainz Miriam Merad, MD, PhD Azaz Ahmed Dyke Ferber Meggy Suarez-Carmona Thomas Walle Journal for ImmunoTherapy of Cancer A.n.n. Frontiers - Immunology Marseille Immunopole Eric Vivier

📢#ESMO22: Three TiP posters on #Mesothelioma this year and 4y data from CM 743! We are proud to present our adjuvant NICITA phase 2 trial (1641TiP) with Chemo +/- Nivolumab after ext. Pleurectomy/decortication. Currently @ 80% recruitment. #LCSM OncoAlert NCT Heidelberg

Visit us @ poster area C for rare thoracic malignancies ESMO - Eur. Oncology #ESMO22 #LCSM #mesothelioma #thymicca 🇫🇷🗼

Great to have Jordi Remon as my poster neighbor ESMO - Eur. Oncology 🙏 #ESMO22 🗼🇫🇷

Warm-up this morning🏃w/ Jonas Kuon, MD prior to the first session ESMO - Eur. Oncology 🗼🇫🇷 ! #ESMOMembers #LCSM

Thrilled to be invited to the annual meeting of German, Austrian and Swiss hem/onc societies to give an update on #mesothelioma and #thymictumors chaired by @SonjaLoges and W. Eberhardt in this admirable city of #Vienna. 🇦🇹🇪🇺 DGHO e. V. @DKG_Berlin #raretumors

The interdisciplinary Symposium on lung metastases - Modern Management is starting shortly today at the Thoraxklinik in Heidelberg. Universitätsklinikum Heidelberg NCT Heidelberg Radiation Oncology @Heidelberg University Hosp. Translational Medical Oncology DKFZ Thoraxklinik

Fantastisch, dass die jungen Kolleg*innen so unterstützt und für das Fach begeistert werden. ✌️

Hi @TwitterSupport the account for OncoAlert 🚨has been locked because we updated the birthday to reflect the start of the network March 25, 2019 In doing so our @TwitterBlue verified account was locked out due to AGE restrictions We're an Oncology⚕️Network ⚠️PLEASE RETWEET‼️

📈 Excited to be presenting our ongoing adjuvant phase 2 RCT #NICITA -trial in progress- w/ nivolumab and chemo in pleural #mesothelioma s/p ePD ASCO 2023. 📢 n=92, t=3yrs, 🎯 Feasible? Visit us at Hall A on 4/June 8 am onwards/ Board227 #LCSM Michael Thomas Martin Reck

It was fantastic discussing screening measurements and future perspectives in treatment of pleural #mesothelioma with participants and representatives of certified mesothelioma centers at the national meeting organized by Institut für Prävention u. Arbeitsmedizin DGUV. 👏

Eric J. Small, MD, FASCO We need to communicate better. Response rate is not cure rate. PFS is not longer life. Amazing to see these points being driven home at the #ASCO24 opening session. The best opening session ever! Completely in line with our philosophy Common Sense Oncology

Osimertinib + SABR in EGFR+ 🔹 Osi x2m, SABR to all sites, cont Osi 👍 mPFS 32.3m 👍 mOS 45m 👍 mDuration on Osi 32.4m 👍 Low Gr3+ AE ❗️small numbers ❗️single arm study ❗️need details of SABR treatment 🤔 survival better than FLAURA 🤔 Pt selection key here #ASCO24 #LCSM

Thank you for stopping by Dr Dr Riyaz Shah